Conclusion
In the realm of paediatric oncology care, a holistic approach is essential to effectively address drug wastage and the associated financial implications. One strategy involves encouraging pharmaceutical manufacturers to tailor vial sizes to meet the unique needs of the paediatric population. Additionally, exploring the feasibility of multi-dose vials with extended stability could prove advantageous. Healthcare providers can also play a crucial role by developing institution-specific protocols for dose rounding and vial sharing, informed by the stability data provided in the package insert. This balanced approach can help optimize resources and improve the efficiency of paediatric oncology drug administration.
Ethical Approval: The study was approved by Institutional Ethics Committee(IEC) number 381/19 dated 28/10/2019
Acknowledgment: We acknowledge Department of paediatric for their constant support
Funding: None
Competing interests: There are no competing interest to declare.
Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.